Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Hutchison MediPharma Starts Clinical Trial of Cancer Drug

publication date: Nov 14, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma, the drug discovery arm of Chi-Med, has begun a first-in-human Phase I clinical trial of epitinib (HMPL-813), the third of MediPharma’s oncology compounds to enter clinical testing. Epitinib is a novel, second generation, orally active, small molecule inhibitor targeting the epidermal growth factor receptor (EGFR). MediPharma hopes epitinib will prove to be effective against brain tumors that have EGFR mutations, either primary brain tumors or tumors metastasized to the brain. More details....

Stock Symbol: (AIM: HCM)     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...